Logo

SXTP

60 Degrees Pharmaceuticals, Inc.

SXTP

60 Degrees Pharmaceuticals, Inc. • NASDAQ
$1.06 ▲ 0.97% (+0.01)
Market Cap $3.42 M
52w High $12.45
52w Low $0.85
Dividend Yield 0%
P/E -1.36
Volume 35.98K
Outstanding Shares 3.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $437.602K ▲ $2.225M ▲ $-2.317M ▼ -529.485% ▲ $-0.66 ▲ $-2.292M ▼
Q2-2025 $100.932K ▼ $1.656M ▼ $-1.734M ▲ -1.718K% ▼ $-1.25 ▲ $-1.713M ▲
Q1-2025 $163.552K ▼ $2.001M ▼ $-1.877M ▲ -1.147K% ▼ $-1.56 ▲ $-1.859M ▲
Q4-2024 $261.44K ▲ $2.219M ▲ $-2.049M ▲ -783.649% ▲ $-4.5 ▼ $-2.032M ▲
Q3-2024 $135.293K $2.142M $-2.16M -1.596K% $-0.88 $-2.144M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.116M ▲ $6.689M ▲ $2.342M ▲ $4.43M ▲
Q2-2025 $1.967M ▼ $4.182M ▼ $1.836M ▼ $2.428M ▼
Q1-2025 $3.451M ▲ $5.978M ▲ $1.949M ▲ $4.11M ▲
Q4-2024 $3.388M ▼ $5.759M ▼ $1.804M ▲ $4.036M ▼
Q3-2024 $5.012M $7.421M $1.458M $6.04M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.315M ▼ $-2.109M ▼ $-25.487K ▲ $4.282M ▲ $2.149M ▲ $-2.119M ▼
Q2-2025 $-1.716M ▲ $-1.45M ▲ $-51.684K ▼ $0 ▼ $-1.485M ▼ $-1.497M ▲
Q1-2025 $-1.877M ▲ $-1.597M ▲ $1.703M ▲ $1.697M ▲ $1.792M ▲ $-1.603M ▲
Q4-2024 $-2.049M ▲ $-1.638M ▲ $-2.098K ▲ $973 ▼ $-1.641M ▼ $-1.64M ▲
Q3-2024 $-2.16M $-1.681M $-1.747M $5.15M $1.724M $-1.72M

Five-Year Company Overview

Income Statement

Income Statement The company is still in the classic early‑stage biotech phase: essentially no product revenue so far and ongoing losses. Reported operating and net losses look small in absolute dollar terms, but the per‑share loss looks very large because of the tiny equity base and the impact of reverse stock splits. In practical terms, the business is still firmly in “investment mode,” spending on development and overhead without any offsetting sales yet. Profitability will depend almost entirely on whether and when its key programs reach approval and commercialization.

Balance Sheet

Balance Sheet The balance sheet is very thin, with modest total assets, minimal or no reported cash, and little to no financial debt in recent years. Equity has only recently moved out of negative territory, helped by capital raises and balance‑sheet cleanup around the SPAC listing and subsequent reverse splits. This structure is typical of a small clinical‑stage biotech, but it also means there is limited cushion to absorb setbacks, and the company is likely to remain reliant on external financing to fund its pipeline.

Cash Flow

Cash Flow Cash flow reflects a pre‑revenue R&D company: money going out for operations and essentially nothing coming in from the business itself. Operating and free cash flow are negative, and there is no meaningful spending on fixed assets, which suggests most cash use is for people, trials, and corporate costs rather than physical infrastructure. Future cash needs will be closely tied to the pace and scale of clinical trials, making access to capital markets or partners a critical ongoing requirement.

Competitive Edge

Competitive Edge Competitively, the company occupies a narrow but potentially important niche in infectious diseases, especially vector‑borne and neglected conditions. Its main edge is a first‑mover push in babesiosis, where there is no currently approved therapy, combined with an already‑approved malaria drug that can be repurposed. This focus on unmet medical need can create a strong position if approvals are achieved. However, the company is small, resource‑constrained, and operates in a field where larger pharmaceutical players could enter if the opportunity proves attractive, so speed and regulatory execution are crucial.

Innovation and R&D

Innovation and R&D Innovation is centered on repurposing tafenoquine, an existing drug with an extensive safety record, and advancing it into new indications like babesiosis. This strategy can shorten development timelines and reduce scientific risk compared with inventing entirely new molecules. Partnerships with the U.S. Army, Yale, and other institutions add credibility and access to data and know‑how, and the babesiosis program has a clear regulatory dialogue in place. A secondary asset, Celgosivir, targets viral infections and offers longer‑term optionality. Overall, R&D is focused, capital‑efficient by design, and aimed at high‑need, under‑served disease areas, but still carries the usual clinical and regulatory uncertainties of drug development.

Summary

60 Degrees Pharmaceuticals is a very early‑stage, highly specialized biotech with no commercial revenue yet, ongoing losses, and a thin balance sheet, which together imply continued dependence on external funding. The investment story is almost entirely about its science and regulatory progress rather than current financial performance. Its main opportunity is to become the first to market with an approved treatment for babesiosis by repurposing an already‑approved malaria drug, supported by strong academic and government partnerships. If clinical and regulatory milestones are achieved, the company’s position in this niche could be meaningful; if not, the limited financial cushion and lack of diversification heighten the business risk. Overall, this is a high‑uncertainty, high‑dependency profile typical of small, clinical‑stage biotechnology firms.

NEWS

November 21, 2025 · 8:01 AM UTC

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

Read more

November 13, 2025 · 1:51 PM UTC

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Read more

October 15, 2025 · 7:14 AM UTC

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Read more

October 9, 2025 · 7:04 AM UTC

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Read more

September 3, 2025 · 8:02 AM UTC

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Read more